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AbstrAct
Objectives The misuse and abuse of prescription opioids 
(POs) is an epidemic in the USA today. Many states have 
implemented legislation to curb the use of POs resulting 
from inappropriate prescribing. Indiana legislated opioid 
prescribing rules that went into effect in December 2013. The 
rules changed how chronic pain is managed by healthcare 
providers. This qualitative study aims to evaluate the impact 
of Indiana’s opioid prescription legislation on the patient 
experiences around pain management.
setting This is a qualitative study using interviews of 
patient and primary care providers to obtain triangulated 
data sources. The patients were recruited from an integrated 
pain clinic to which chronic pain patients were referred from 
federally qualified health clinics (FQHCs). The primacy care 
providers were recruited from the same FQHCs. The study 
used inductive, emergent thematic analysis.
Participants Nine patient participants and five primary care 
providers were included in the study.
results Living with chronic pain is disruptive to patients’ lives 
on multiple dimensions. The established pain management 
practices were disrupted by the change in prescription rules. 
Patient–provider relationships, which involve power dynamics 
and decision making, shifted significantly in parallel to the rule 
change.
conclusions As a result of the changes in pain management 
practice, some patients experienced significant challenges. 
Further studies into the magnitude of this change are 
necessary. In addition, exploring methods for regulating 
prescribing while assuring adequate access to pain 
management is crucial.
bAckgrOund
The misuse and abuse of prescription 
opioids (POs) is an epidemic in the USA 
today. Since 1999, the rate of drug over-
dose deaths in the USA has doubled in 29 
states, tripled in 10 states and quadrupled 
in 4 states, including the State of Indiana.1 
In 2013, physicians wrote over 200 million 
prescriptions for opioids, and over 2 million 
Americans suffered PO use disorders.2 The 
societal costs of PO abuse, including lost 
productivity and increased utilisation of 
healthcare, were estimated at $55.7 billion 
in 2007.3 Not surprisingly, there is growing 
evidence for a correlation between consump-
tion levels of POs and measures of morbidity 
and mortality, including PO overdose-re-
lated deaths and admissions to substance use 
disorder treatment programme.4 According 
to the 2012 National Survey on Drug Use and 
Health, Indiana ranked third for non-med-
ical PO use (NMPOU): an estimated 5.63% of 
its residents aged 12 years and older reported 
NMPOU in the prior year.5 In the same year, 
Indiana ranked ninth among US states for 
opioid prescribing, with a rate of 109.1 per 
100 000 residents.6 In 2012, 999 Indiana resi-
dents died of drug overdose, an increase of 
57% over the prior decade.7 
Many states have implemented legislation 
to curb the use of POs resulting from inap-
propriate prescribing.8 Legislative strategies 
include oversight by prescription monitoring 
programme, the regulation of pain clinics 
and the establishment of PO dosage thresh-
olds above which pain expert consultation 
is mandatory.8 Indiana legislated opioid 
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Research
strengths and limitations of this study
 ► Strengths of the study include the features of its 
design including the qualitative interview of patient 
and healthcare providers, the triangulated data 
sources and data analysis,  and the selection of 
patients from underserved patient populations.
 ► Sampling the providers from the same clinics 
provides support for the trustworthiness of the 
patients’ accounts.
 ► The study captured in depth the experiences of 
patients post policy implementation.
 ► Limitations of the study include the smaller sample 
size.
 ► The study does not reflect the full spectrum of 
patient experiences post policy.
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prescribing rules (Title 844 IAC Article 5, Rule 6) that 
went into effect on 15 December 2013.9 The new regu-
lations, while not setting a ceiling on opioid prescribing, 
require physicians to (1) screen patients receiving POs 
for psychiatric conditions, (2) review patients’ drug 
prescription history in Indiana’s drug monitoring data-
base (INSPECT), (3) perform regular drug tests and (4) 
require patients on POs to sign a controlled substance 
agreement.9
Studies evaluating state-level initiatives’ impact 
on opioid prescription rates and related morbidity 
and mortality have indicated significantly lower PO 
prescribing but mixed evidence of a favourable impact on 
death by drug overdose.6 10 The new Indiana rules have 
been associated with a similar decrease in the volume of 
prescribed opioids; the impact of the policy, however, 
differs by gender, age and payer types.11 12 The impact was 
larger for men than for women, for younger rather than 
older patients and for Medicaid and Medicare patients 
when compared with patients with private insurance.13 
The ‘success’ of state policies in curbing the over prescrip-
tion of opioids, however, raises two concerns. First, the 
sharp decline in opioid prescription rates suggests the 
excessive application of prescription guidelines, which 
may consequently (and unintentionally) result in the 
under treatment of pain.14 Second, the varying rates of 
decline across subpopulations may be an indicator of 
disparity in an area of patient care that is already laden 
with disparities.11 12 Pain experts agree that individuals 
with a legitimate need for pain control should have access 
to adequate pain management.15 16 However, there is little 
consensus about how to restrict the overprescribing of 
opioids, which results in misuse and abuse, while simulta-
neously maintaining legitimate access to pain care.17 This 
delicate balance is further complicated by considerations 
such as the impact on patient satisfaction, patient empow-
erment or the patient–provider/prescriber relationship.
This paper’s aim is to evaluate the impact of Indiana’s 
opioid prescription legislation on the patient experiences 
with pain management. The study explores the rules’ effect 
on decision making and satisfaction with the prescriber–
patient partnership and presents patients’ perspectives, 
which often go unheard. To enhance the trustworthiness of 
the findings and provide confirmation of the clinical prac-
tices that define patients’ experiences, the triangulation of 
participants was used to supplement patient accounts of 
experienced pain with the healthcare providers account of 
experienced pain management. The actual experiences of 
patients will help deepen understanding of the implemen-
tation of the rules and may also provide insight into the 
patterns observed in previous quantitative studies.
MethOds
setting
Patients were recruited from clinics in a safety net health 
system, which consists of a set of healthcare facilities that 
provide care to the indigent and underinsured patients. 
Patients receiving care at these clinics have diverse racial 
backgrounds, and most are either Medicaid insured or 
underinsured. The selection of the site was based on the 
assumption that patients with a lower socioeconomic 
status are more likely to be negatively affected by the PO 
rules.
sampling, eligibility and recruitment
Critical case sampling, a type of purposive sampling, was 
used to recruit participants. This sampling technique is 
particularly useful in exploratory qualitative research, as 
it permits logical generalisation and maximum applica-
tion of results to other cases, that is, ‘If this is true for this 
case, it is likely to be true of others.’18 Patients who have 
chronic pain were eligible for the study if they met all of 
the following criteria: (1) received pain treatment through 
the health system’s integrative pain programme (IPP) 
after the December 2013 policy change, (2) had been on 
long-term opioid therapy for a chronic pain condition for 
at least 1 year prior to policy implementation and (3) were 
proficient in English. Primary care providers (PCPs) were 
eligible to participate if they had been practising at one 
of the clinics in the system for at least 1 year prior to the 
enactment of the Indiana rules. We recruited these PCPs 
via email. The interviewer (Al Achkar) has no previous 
relationship with any of the patient participants. Two of 
the provider participants have teaching privileges at the 
interviewer’s institute. MacKie provides care and oversee 
the IPP. He also works in the same health system with the 
provider participants. One patient refused to participate 
for no given reason. One provider also refused to partici-
pate due to time constraints.
Interview instruments
We designed a semistructured interview with a set 
of core questions and follow-up probes that were 
informed by literature and consultation with and input 
from a pain management specialist (see online supple-
mentary appendix 1). Both the provider and patient 
interviews started with explaining the purpose of the 
study. The patient interview addressed patient descrip-
tions of pain, experiences of pain before and after 
the policy change, perceptions about the impacts of 
the new policy, patient–provider communications and 
relationships before and after the policy change, and 
satisfaction with treatment/management before and 
after the policy change. The provider interview focused 
on the experience of managing pain before and after 
the implementation of the rules, knowledge of the 
rules and satisfaction with practice. Interviews lasted 
between 30 and 45 min on average. Interviews were 
performed until saturation was reached. Saturation was 
determined after the initial discussions between the 
qualitative researchers as the data were collected. The 
interviewer is a PCP and residency educator with a posi-
tion that emphasise providing effective, equitable and 
safe care to all patients.
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Table 1 Study participant characteristics
Age Gender Location of chronic pain Pain duration Currently on opioids?
Patients*
  HQ 45 F Knee 5 years Y
  SW 42 F Neck, shoulder, back Y
  LJ 61 F Knee 18 years Y
  GW 43 M Shoulder, back 12 years N† 
  EM 43 M Hip, back, neck 12 years Y
  NC 73 F Back, legs, arms, hands 42 years Y
  RJ 54 F Back, knees 15 years Y
  IS 58 M Neck, back Y
  DJ 63 F Neck, arm, back 13 years Y
Gender Specialty % of patients with chronic pain
Doctors*
  Dr RC M Internal medicine 20%–30%
  Dr AM M Internal medicine 30%
  Dr NB F Internal medicine 10%
  Dr KS M Family medicine 15%
  Dr PY M Family medicine 30%–50%
*The letters represent the initials of the participants’ given pseudonames.
†This patient was on opioids in the past but was taken off opioids at the time of the interview.
Interview protocol
Interviews with patients were conducted by phone by Al 
Achkar between July and December 2015. We conducted 
interviews with providers in person except for one 
provider who completed the interview by phone. The 
in-person interviews were conducted at the participants’ 
offices (three interviews) or at Al Achkar’s office (one 
interview). All interviews were audiotaped, and partici-
pants received a $50 gift card at the conclusion of the 
interview. No one was present during the interviews 
besides the participants and the researcher.
Analysis
Audiotapes were transcribed verbatim and imported 
into Dedoose, a web-based application for managing, 
integrating and analysing qualitative data.19 A member 
of the analytical team (Al Achkar) added descriptors 
to each transcript that included demographic informa-
tion. Three team members (Al Achkar (male), Revere 
(female), Dennis (female)) participated in an induc-
tive, emergent thematic analysis.18 20 Team members 
individually read transcripts several times and subse-
quently met to discuss initial impressions. The sections 
of the interviews that are focused on the patient and 
provider experience with pain and pain management 
were selected for in depth analysis. Thematic analysis 
involves taking the perspective of the interviewees in 
order to code the meanings of participant talk in an emic 
(or internally consistent) way. Al Achkar, Revere and 
Dennis read through the transcripts, talked through the 
meanings and articulated code names to indicate the 
various interpretations. Then, relationships across the 
initial codes were developed through dialogue across 
researchers about the meanings. To enhance the rigour 
of the study, team members independently coded the 
data and then collaboratively reconciled the codes until a 
classification scheme was developed. Discrepancies were 
identified and resolved by consensus throughout the 
analysis. Excerpts from the transcripts of the participants 
and providers were selected to support the themes. This 
paper is the result of collaborative efforts and dialogues 
between researchers from different philosophical back-
grounds. All the authors reviewed the manuscript and 
contributed to the background and discussion.
FIndIngs
characteristics of the sample
Nine chronic pain patients (CPPs) and five PCPs partici-
pated in the study. Table 1 describes the participants.
themes and subthemes
As outlined in table 2, three overarching themes with 
associated subthemes emerged across both CPP and 
PCP groups: (1) living with chronic pain is disruptive in 
multiple dimensions; (2) established pain management 
practices were disrupted by the change in prescription 
rules; and (3) patient–provider relationships, which 
involve power dynamics and decision making, shifted 
in parallel to the rule change. Detailed results for each 
theme are as follows.
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Living with chronic pain is disruptive in multiple dimensions
Embedded within this central theme are three subthemes 
that include CPPs report a wide range of emotional 
responses associated with their pain experience; unman-
aged chronic pain disrupts the relationships CPPs have 
with others; CPPs experience ongoing challenges to their 
quality of life (QOL); POs can help with daily functioning, 
but their effect is not persistent or long lasting and have 
negative side effects.
Most CPPs reported feelings of depression, anxiety, 
frustration and anger about their pain experience. 
Living with chronic pain has disrupted their lives, led 
to unemployment or underemployment, reduced their 
ability to engage in activities they formerly enjoyed and 
undermined their sense of autonomy and independence, 
despite receiving pain treatment and medication.
I’ve not gone to work and don’t even go out. I don’t 
go out with my husband. I don’t go out with my 
daughter. I don’t go out with anybody. (…) My life is 
pretty much at a standstill. (HQ)
I get irritable. (…) Sometimes I get more aggravated. 
(…) I get impatient a lot. A little sadness too. (IS)
(Pain) affects your relationships because it affects 
your attitude. (…) Sometimes, somebody might want 
to talk to you or whatever and you are in pain and you 
don’t mean to be mean and rude or not responsive. 
(…) You just don’t wanna move; you just wanna sit 
there because of how bad you hurt and that’s not fair 
to the person that you are with. (EM)
I can’t do the things that I used to do and it kind of 
makes you feel like you can’t do anything. (…) You 
have to depend on people to do stuff for you because, 
like I said, I can’t even walk from here to the bus stop. 
(MN)
…to have to ask for help (…) to use instruments just 
to put your clothes on, tie your shoes, pick something 
up off the floor or, you know, just the normal daily 
stuff that people take for granted. (RJ)
While POs provided some relief, they alone were not 
sufficient for managing pain and were frequently consid-
ered ineffective, particularly when adverse side effects 
were taken into account. However, the use of non-PO 
medications and approaches also varied in effectiveness.
(Pain medications) would give me the shakes, not 
visual but the way I talked. My speech would be a little 
slurred and I just didn’t like the effect. (KD)
…after so long (pain medications) just seemed that 
they just didn’t work; they were only making me tired 
(…) and the injections only lasted for 10, 15 min. By 
the time I made it to the car, it was over. (…) the 
injections, the medicated rub, pain relief rub, and 
Ibuprofen, Proxen, I’ve tried everything, you know? 
Cold packs for my knees and hot packs to my knee, 
you know, they only work for a small period of time. 
(HQ)
I try to put like a heating pad on (my knees) to kind 
of control it while I sleep and then it kind of feels a 
little better but soon as I take it off, I mean, if I get up 
and I’ll just try to walk or try to move on it, it kind of 
starts back. (MN)
Established pain management practices were disrupted by the 
change in prescription rules
Three subthemes emerged regarding the impact of the 
rules on perceptions of providing and experiencing pain 
management by providers and patients, respectively. 
These include the following: after the rules, patients 
experienced changes in medication regimen; the 
multiple layers of ‘vetting’ were disruptive; lack of care 
coordination with requirement to see pain specialists and 
additional providers.
Patients mentioned changes in their medications or 
medication regimen, having to undergo new protocols 
such as needing to be ‘vetted’ for medications by frequent 
urine screens, having more frequent doctor appoint-
ments, being given lower pill allowances that necessitated 
more frequent refills and pharmacy visits, and needing 
to see multiple providers for pain management. Some 
patients were taken off prescribed opioids when their 
drug screen results were inconsistent. During office visits, 
patients underwent additional monitoring procedures, 
such as pill counting and urine drug screening, among 
others.
(The doctor) kept lowering the medicine every 
month, lowering it down. (…) I’m still going in pain. 
(NC)
I get drug tested about (every) 2 or 3 months. (…) I 
think it (the rules) made it more difficult for patients 
to get their medicines (…) it’s hard to take off work 
to be able to go in every month or 2 months to the 
physician, whereas it used to be able to get refills 
every 3 to 4 months without having to go to the 
physician. (Now) it’s usually every 6 weeks I see (the 
pain management) doctor. (IS)
PCPs also described the change in rules as impacting 
their approach to pain management, their prescription 
practices and both the frequency and focus of their 
appointments with CPPs. Providers had to reconcile their 
enforcement of the law with how to best treat patients 
with chronic pain. On occasion, the providers’ practices 
were even more restrictive than the mandates of the rules 
themselves, especially with respect to setting a ceiling on 
prescribing.
I prescribe lower volumes of opiates and patients 
that were on higher (…) morphine equivalent 
doses previously, I brought it down to much lower 
levels. (The law) effectively set a ceiling on (…) 
how much, what volume of opiates I’d prescribe 
to a patient. (…) It’s really made us formalise a 
lot of what we do in terms of (…) how frequently 
we see the patients. (…) We don’t just tell them to 
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come every 3 months; we force them to come every 
3 months. (Dr AM)
In addition to lower dosages, more strenuous moni-
toring activities and more frequent appointments and 
prescription refills, some patients were also required to 
attend chronic pain self-management classes or see allied 
health providers such as occupational therapists. For 
CPPs who were employed, these requirements placed 
an additional burden on their lives, which were already 
disrupted by chronic pain.
(The law) affects people like me (who are employed) 
because they won’t give (opioids) to you unless, 
you know, you go (…) to the special clinic, the 
classes, to get them. Well, I knew that I couldn’t get 
(medications) until I went to the classes. I had to go 
to the classes in the winter. I had to hop out and catch 
the bus and go out west to go to the (pain) clinic to 
see the doctor. (MN)
The new and stricter monitoring requirements led 
some PCPs to refer their CPPs to pain management 
specialists who became overwhelmed by the demand. In 
addition, some CPPs experienced confusion when their 
primary and specialty care were not well-coordinated.
…after the policy came in (the pain) clinic got 
saturated. (…) I think it might have been a little 
harder to get into physical therapy and even into 
anaesthesia too. (Dr NB)
My rheumatologist tells him not to change my medi-
cine but he changes it anyway. (EM)
Patient–provider relationships, with respect to power dynamics 
and decision making, shifted in parallel to the rule change
Six subthemes related to a reversal or shift in power 
dynamics and patient centredness emerged from both 
CPP and PCP interviews. These include the following: 
the rule change shifted power and privilege that disem-
powered patients; providers found the law effective in 
supporting their need to change pain management 
and lower prescriptions; patients perceive themselves as 
being objectified by providers; the objectivity of the rule 
and accompanying testing changed the patient from a 
person in pain to a public health problem that needed to 
be objectively addressed; the law overshadows caring for 
patients; patients experienced disenfranchisement that 
adversely impacted their trust of their doctors Providers 
were empowered by the law to change their pain manage-
ment approach or to enforce changes they had struggled 
to implement prior to the rule change.
Personally, I was happy because I never really believed 
in heavy use of narcotics to begin with (…) so I was 
grateful that finally I didn’t have to say it was me 
being the bad guy. (…) I could point to the laws and 
policy around this and use that kind of statement 
with the patients to say that, ‘It’s not that I don’t want 
to give you these narcotics or more narcotics, we are 
not allowed to and we must document any change 
or escalation because the law’s requiring it.’ (…) It 
felt like a scapegoat in some ways, but in a way it felt 
like support, so I actually used it to my advantage. 
(Dr NB)
(The law has) given me support in drawing lines with 
patients to not only say, ‘No, I won’t prescribe that to 
you because I don’t think it’s likely to help you.’ Some 
patients will argue that point endlessly, but if you say, 
‘No, I won’t prescribe that to you because it’s not 
likely to help you and I’m not allowed to.’ (Dr PY)
These are the rules. You know the rules. They’re not 
my rules. Uh, this is the law and we can both agree 
that, you know, and those situations really practice in 
a way that’s against the law. Hum, and so this makes 
it, it makes it more clear and objective and greatly 
reduces that kind of degree of emotional energy that 
was stressful prior to that. (Dr KS)
In fact, some PCPs viewed the law as improving their 
practice with respect to CPPs.
I think people that were really actively drug seeking 
before being effectively weeded or weaned out of the 
system. I think a lot of them are using heroin, but you 
know they’re not coming to my clinic and yelling at 
me and yelling at my staff and threatening people. 
(Dr PY)
Parallel with the rule change, some patients experi-
enced a change in their relationship with their PCPs, 
from one in which they perceived that their needs and 
struggles were being heard and acknowledged to a rela-
tionship in which the law dictated changes in medication 
and changes in the quality of the provider encounter. 
This changed the patient’s relationship from one where 
they felt heard and involved in the treatment process to 
one in which they felt controlled and treated in a more 
objective manner.
They didn’t really allow me to speak about anything 
or tell them anything: they just came in and looked 
at me real quick. (…) The thing is that the doctor 
just don’t (…) want to listen to me about my pain. 
They just… it’s like they thought that I was making 
it up or something just try to get the medicine. They 
made me feel like (…) I was an addict trying to get 
fixed. (IS)
The doctors… you know, have too much control 
of… of the patient’s care. The patient and the doctor 
should be a team. (…) It seems to me that the patient 
should come first. Ah, ah, I mean, isn’t that what, 
what the doctor, one of the doctor oaths? Didn’t they 
take the oath to help their patient? (EM)
Indeed, PCPs acknowledged that the law created a 
firmer boundary between their patients and themselves, 
leading to less personal or less patient-centric encounters 
and relationships.
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(The law) shapes the conversation with patients 
about facing an expectation and then requirements 
and, uhm, boundaries, and makes the interaction 
more objective. (Dr KS)
I’m managing them more appropriately even though 
they may be less satisfied. (Dr RC)
Some patients expressed feeling less as individuals and 
more as an abstract public health problem that insti-
gated the rule change in the first place. CPPs expressed 
an inability to negotiate this dynamic. Patients often 
used a passive voice when describing this change, seeing 
themselves as witnesses to the changes happening to 
them.
I don’t care about people overdosing. I don’t care 
about people getting robbed on the street because 
I’m not the person that’s doing that; the only thing 
that I care about is my health (and) my quality of life. 
(…) What does (the law) have to do with the person 
that’s in front of (the doctor) in a wheelchair – they 
can’t walk, they can’t do this, they can’t do that, but 
they’re in pain but you’re telling them that, ‘Oh, we 
can’t give you any pain medicine.’ (EM)
(The new law) messes up people that don’t use drugs 
and the ones that do use it, that’s on them. I don’t put 
nothing in my body that’s not prescribed by a doctor. 
(MN)
Both patients and providers started to feel as if that 
the main focus of the patient–provider relationship 
is enforcing the legal requirements regarding pain 
management.
So I stopped allowing the escalation, even, you 
know, that I just did out of maybe sympathy instead 
of objective and I started de-escalating (…) a lot of 
people, because of the (…)risk of managing these 
individuals (or) having someone say that you’re 
doing something. (It) made this more sensitive to 
even prescrib(ing) opioids. (Dr PY)
I was doing just fine (before the law change). Now I 
have to struggle, suffer, to make to the next time that 
I can get my medicine. And I don’t think it’s fair to 
me because if I can take my medicine a little more 
regularly, I would be able to do more and thought 
that we have a better effect in your life and I don’t 
think that law, people, politicians, or anybody should 
be able to tell anybody that’s in pain what type of 
medicine that they can take. (EM)
However, patients who felt cared for and listened to 
tended to trust their PCP, despite needing to comply with 
the rule change.
I really felt like (the pain management doctor) and 
all of the team, they really did help me; they really 
did. They really did and got me on the way to where 
I need to be. (HQ)
This highlights a division among CPPs: the shift in the 
power dynamic and decision making between patient 
and provider was seen as adversely impacting the patient–
provider relationship depending on patient perceptions 
of trust and caring and changes in provider practices 
after the rules. Some CPPs viewed their providers as pref-
erentially treating other patients, despite the law, while 
other CPPs expressed anger and extreme dissatisfaction 
with treatment to the extent that they planned to change 
providers.
I know some women that smoke pot and do other 
drugs and he’s prescribing them pain meds and giving 
them drugs and not treating the women like he does 
the men. I just think that he is playing favouritism 
towards the women. (…) (In fact) I don’t care to see 
that doctor right now, am in the process now of trying 
to find another doctor. (VN)
(My doctor is) the coldest person you have ever 
seen in your life. (…) He don’t care. I come at him 
crying… I can’t stand the bastard. I will tell him what 
shape I am in and he just ignore it. (…) (As a) matter 
of fact, I signed up for another doctor; they don’t 
know it yet but I signed up with another doctor. (NC)
In summary, a range of perceptions and experiences 
associated with the PO law change were described as 
creating barriers to effective pain management, both 
self-management by CPPs and pain management prac-
tices by PCPs.
dIscussIOn
Chronic pain is a complex, subjective phenomenon that 
is, our study confirms, disruptive to a person’s day-to-day 
experiences and can greatly reduce QOL. We found that 
in subjective matters like pain, the patient's personal 
narrative is critical for healthcare providers who are 
designing and providing an effective pain management 
plan; however, the Indiana PO law change disrupted estab-
lished pain management practices as well as shifted the 
power dynamics and decision-making relationship that 
are built on these shared narratives between providers 
and their patients.
A number of factors were described by patients as 
hindering their perception of ‘being heard’ regarding 
their pain experiences, particularly the mandate to use 
objective measurements of pain levels and ancillary expe-
riences, such as surveys to screen for other health condi-
tions and urine drug screening. While these measures can 
support understanding, collaboration and shared deci-
sion making in the context of the new PO rules, relying 
on these ‘objective’ scales are perceived by patients as 
diminishing their providers’ ability to truly understand 
their pain. Patients viewed these tools as creating or 
increasing barriers to effective pain management, by 
increasing the frequency of these office visits, reframing 
the pain experience in an ‘objectifying’ way and, overall, 
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diminishing empowerment in regard to patient autonomy 
and decision-making.
In response to the opioid use crisis that stemmed 
partially from laxed used of PO, the Indiana prescribing 
rules were developed to regulate prescribing and to foster 
a more biopsychosocial approach to pain management 
by increasing the contextual understanding of individ-
uals and their unique experiences of pain, suffering and 
expectations.9 However, the providers’ practices and 
patient experiences suggest that the new rules have over-
empowered doctors to leverage the force of the law while 
transforming patient pain management into an adminis-
trative task. Some patients feel more marginalised as they 
are being denied medications and receiving impersonal 
care that fails to address their needs while focusing on the 
public health opioid epidemic—an epidemic they believe 
they have no part in.
Because patients perceive a disruption in the focus and 
goals of treatment, they are left feeling unheard, disem-
powered and even cheated. Many patients now endure 
additional struggles to obtain access to pain management 
and must adhere to requirements—in some circum-
stances, such as the urine drug testing, not paid for by 
some insurers, which add financial burden to both clinics 
and patients—to demonstrate their compliance with the 
demands of healthcare providers and the law. For some 
patients, such barriers are insurmountable; consequently, 
they seek care from different providers who might be more 
sympathetic or less rigid regarding clinical oversight.
In addition to disrupting prior pain management 
practices and shifting patient centredness priorities, we 
found that the concept of effective pain management is 
perceived by providers and many patients as an ‘unwin-
nable fight’ due to the complexity of subjectively expe-
rienced pain, the myriad conditions that lead to chronic 
pain, suboptimal effects achieved by most treatments and 
the risk of harm inherent in some treatment options. 
Opioids lack evidence for long-term effectiveness and can 
be detrimental to individuals and society as a whole when 
they are used excessively, abused or diverted. Thus, the 
decision to prescribe opioids can be difficult.
However, the findings presented here should not be 
understood or employed to reject or revise a law arbi-
trarily. Beyond the benefits that have already been 
reported about decreasing drug abuse and mortality,10 21 
new legislation may be playing a role in bringing pain to 
the forefront of the doctor/patient interaction. Our find-
ings invite the reader to reflect on the opioid prescription 
rules and their implementation in practice. Pain cannot 
be reduced exclusively to numbers, and a patient’s expe-
rience cannot be fully characterised with surveys, even 
if such measures assess depression, anxiety and risk of 
abuse. This study attempts to add to the dialogue about 
how patient care can be centred on the patient while still 
providing safe and effective care and shared decision 
making between patients and providers. Furthermore, 
the study provides evidence to support the national 
initiatives and patient-led organisations that aim to give 
patients a stronger voice in the discussion around health-
care reforms and to empower them in their day-to-day 
encounters with healthcare providers.
While this study gave voice to patients and presented 
providers’ perspectives to validate their stories, it has 
limitations. First, the critical sampling of 14 partici-
pants may have highlighted certain aspects of patients’ 
and providers’ experiences while obscuring others. 
However, it can be argued that selecting patients from 
safety net clinics where the majority were either under-
insured or uninsured gave voice to more vulnerable and 
often under-represented patients. Second, while the 
study presented perspectives of patients and providers, 
no attempt was made to correlate findings between the 
two groups or conduct cross-confirmatory analysis. None-
theless, by sampling from the same clinic, it is likely that 
the two groups together represent a shared experience 
within the culture and space of the clinic. Moreover, 
to the best of the authors’ knowledge, this study is the 
first to capture patient–provider experiences post policy. 
Finally, this work provides a foundation for much-needed 
future quantitative research studying the experiences of 
a broader patient population. Doing so would provide 
practitioners and researchers with a more comprehensive 
assessment the opioid prescribing rules.
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